Normal Plasma Levels of Cardiac Troponin I Measured by the High-Sensitivity Cardiac Troponin I Access Prototype Assay and the Impact on the Diagnosis of Myocardial Ischemia
被引:137
作者:
Venge, Per
论文数: 0引用数: 0
h-index: 0
机构:
Uppsala Univ, Dept Med Sci, Uppsala, Sweden
Uppsala Univ, Dept Clin Chem, Uppsala, SwedenUppsala Univ, Dept Med Sci, Uppsala, Sweden
Venge, Per
[1
,2
]
Johnston, Nina
论文数: 0引用数: 0
h-index: 0
机构:
Uppsala Univ, Dept Cardiol, Uppsala, SwedenUppsala Univ, Dept Med Sci, Uppsala, Sweden
Johnston, Nina
[3
]
论文数: 引用数:
h-index:
机构:
Lindahl, Bertil
[3
,4
]
论文数: 引用数:
h-index:
机构:
James, Stefan
[3
,4
]
机构:
[1] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[2] Uppsala Univ, Dept Clin Chem, Uppsala, Sweden
[3] Uppsala Univ, Dept Cardiol, Uppsala, Sweden
[4] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
troponin I;
unstable angina;
myocardial infarction;
CORONARY-ARTERY-DISEASE;
MEDICINE PRACTICE GUIDELINES;
CLINICAL BIOCHEMISTRY;
NATIONAL ACADEMY;
UNSTABLE ANGINA;
DEFINITION;
BIOMARKERS;
ABCIXIMAB;
OUTCOMES;
D O I:
10.1016/j.jacc.2009.05.051
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objectives This study sought to evaluate the analytical and clinical performance of the novel hypersensitive cardiac troponin I (cTnI) prototype assay from Beckman Coulter (Fullerton, California). Background Studies on patients with acute coronary syndromes and on seemingly healthy subjects have shown that even very minor elevations of cardiac troponins are associated with an increased risk of death. However, the normal plasma levels of cardiac troponins are still not known. Methods cTnI plasma levels were measured in 542 healthy subjects, 319 men (age 59.9 +/- 11.8 years) and 213 women (age 59.8 +/- 13.1 years), and in 1,503 randomly selected patients of the GUSTO IV (Global Utilization of Strategies To open Occluded arteries IV) cohort with unstable angina and non-ST-segment elevation myocardial infarctions (MIs). Results The cTnI levels at 10% coefficient of variation and 20% coefficient of variation imprecision were 0.0033 and 0.0016 mu g/l, respectively. The cTnI levels were measurable in >95% of the healthy subjects. The median level of healthy subjects <60 years of age was 0.0032 mu g/l (range 0.0011 to 0.0079 mu g/l) with the 99th percentile being 0.010 mu g/l. No sex differences were observed. A receiver-operator characteristic curve analysis showed an optimal discrimination between healthy subjects and patients at 0.0064 mu g/l with a sensitivity of 84.8% (95% confidence interval: 82.8% to 86.6%) and specificity of 89.7% (95% confidence interval: 86.8% to 92.2%). Outcomes as to death and/or MI were significantly different at this level (p < 0.01) in the GUSTO IV cohort. Conclusions The novel high-sensitivity cTnI prototype assay from Beckman Coulter allows for the first time the measurement of cTnI levels in almost all healthy subjects. Our data indicate that the assay may be a powerful aid in the diagnosis and outcome prediction of patients with suspected myocardial ischemia and question any definition of myocardial infarction. (J Am Coll Cardiol 2009; 54: 1165-72) (C) 2009 by the American College of Cardiology Foundation